Cost-Effectiveness Analysis of Anticoagulation Strategies in Non-ST-Elevation Acute Coronary Syndromes

200912 citationsJournal Article

Authors

Carleton B. Maxwell · Jackson-Madison County General Hospital

David A. Holdford · Virginia Commonwealth University

Dipen Patel · Virginia Commonwealth University

Abstract

Bivalirudin is the least costly agent in moderate- to high-risk NSTE-ACS patients managed with an early invasive approach, if its use is consistent with the ACUITY trial. Fondaparinux is the preferred agent in patients undergoing a conservative treatment strategy.

Topics & Keywords

Acute Myocardial Infarction Research Venous Thromboembolism Diagnosis and Management Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Pharmacotherapy

Volume 43, Issue 4, pp. 586-595

DOI: 10.1345/aph.1l498

Field-Weighted Citation Impact: 1.45